ICI-118,551

ICI-118,551

200px
Names
IUPAC name 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol
Identifiers
CAS Number	72795-19-8 Y
ChEMBL	ChEMBL513389 N
Jmol 3D model	Interactive image
MeSH	ICI+118551
PubChem	3682
SMILES CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
Properties
Chemical formula	C17H27NO2
Molar mass	277.402 g/mol
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

ICI-118,551 is a selective beta-2 (β₂) adrenergic receptor antagonist. ICI binds to the β₂ subtype with at least 100 times greater affinity than β₁ or β₃, the two other known subtypes of the beta adrenoceptor. The compound was developed by Imperial Chemical Industries, which was acquired by AkzoNobel in 2008.

ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β₂ adrenergic receptor, as few other specific antagonists for this receptor are known. When dissolved in saline, the compound crosses the blood–brain barrier. Common systemic doses used in rodent research are .5 or 1 mg/kg although efficacy has been demonstrated at doses as low as .0001 mg/kg in rhesus monkeys. Doses up to 20 mg/kg have been used without toxicity. At room temperature in saline, the ICI 118,551 hydrochloride is soluble to at least 2.5 mg/mL.